Who is sponsoring NCT04756271?

NCT04756271 is sponsored by Zagazig University.

What drugs are being tested in NCT04756271?

Interventions in NCT04756271: SARS-Cov-2 neutralizing antibody titer.

What condition does NCT04756271 study?

NCT04756271 studies Vaccine Adverse Reaction, Seroconversion.

Is NCT04756271 still recruiting?

NCT04756271 is currently completed. Last updated 9 February 2022.

Last reviewed 2022-02-09 · How we verify

NCT04756271

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection

Completed Phase 3 Last updated 9 February 2022

What this trial tests

Phase 3 trial testing SARS-Cov-2 neutralizing antibody titer in Vaccine Adverse Reaction in 246 participants. Completed in 22 December 2021.

Timeline

11 February 2021

Primary endpoint
20 December 2021

22 December 2021

Quick facts

Lead sponsor	Zagazig University
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	246
Start date	11 February 2021
Primary completion	20 December 2021
Estimated completion	22 December 2021
Sites	1 location across Egypt

Drugs / interventions tested

SARS-Cov-2 neutralizing antibody titer — full drug profile →

Conditions studied

Vaccine Adverse Reaction — all drugs for Vaccine Adverse Reaction →
Seroconversion — all drugs for Seroconversion →

Sponsor

Zagazig University

Who can join

18 and older, any sex, with Vaccine Adverse Reaction or Seroconversion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

After SARS-COV-2 inactivated vaccine authorization for use in different countries including Egypt, investigating its immunogenicity, safety, and efficacy in preventing COVID-19 infection is highly needed. In Egypt, immunization of HCWs in isolation hospitals by SARS-COV-2 inactivated vaccine is now a national priority. Moreover, data and reports regarding the application of vaccine are still limited and deficient.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Nanoparticles in clinical trials of COVID-19: An update.
Rauf A, Abu-Izneid T, Khalil AA, Hafeez N, et al · · 2022 · cited 22× · PMID 35953020 · DOI 10.1016/j.ijsu.2022.106818
Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection.
Al-Hatamleh MAI, Abusalah MA, Hatmal MM, Alshaer W, et al · · 2023 · cited 7× · PMID 36570799 · DOI 10.1016/j.jtumed.2022.11.007

Verify or expand the search:

Other recruiting trials for Vaccine Adverse Reaction

Currently open trials in the same condition.

NCT06180447 — Peri-conceptional or Pregnancy Exposure of Vaccination and the Risk of Adverse Pregnancy Outcomes · active not recruiting
NCT05898464 — Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV · Phase 4 · active not recruiting
NCT06286488 — Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza · Phase 4 · active not recruiting

Other Zagazig University trials

Trials by the same sponsor.

NCT07423676 — Comparison Between Two Drugs in Sedation of Upper GI Endoscopy · not yet recruiting
NCT07418307 — Comparison Between Combined Biceps Femoris Short Head Block and Adductor Canal Block Versus Genicular Nerve Block · NA · not yet recruiting
NCT07435025 — Surgery for Obstructed Gastric Carcinoma · NA · active not recruiting
NCT07330375 — Effect of Intravenous Dexmedetomidine and Ketamine on Post-Operative Analgesia · Phase 3 · not yet recruiting
NCT07309731 — Impact OF Cooled Versus Thermal Radiofrequency Denervation In Management Of Chronic Lumber Facet Joint Pain · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04756271 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zagazig University
Last refreshed: 9 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04756271.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing